The SARS-CoV accessory protein 7a is a type I membrane protein with an extracellular domain of 81 amino acid residues. It is described to be expressed during infection and to be a component of the virus particle surface. In this study, we demonstrate that protein 7a binds directly and specifically to human lymphocyte function-associated antigen 1 (LFA-1) on the cell surface of Jurkat cells. The binding is increased upon artificial cell activation with phorbol ester. These observations are confirmed by direct in vitro binding of recombinant protein 7a to the wild type and mutant K287C/K294C I domain showing that the I domain is the 7a binding site in the a L chain of LFA-1. Consequences of the LFA-1 interaction with 7a are discussed. In particular, our data suggest LFA-1 to be an attachment factor or the receptor for SARS-CoV on human leukocytes.
Introduction
A novel coronavirus (CoV) has been shown to be the etiologic agent of the severe acute respiratory syndrome (SARS) epidemic, which affected thousands of people from November 2002 to July 2003. The viral positivestrand RNA genome is almost 30 kb in length and contains 14 potential open reading frames. The characteristic features of coronaviruses are two overlapping open reading frames (ORF1a and ORF1b) that code for the 'replicase', which is further processed into non-structural proteins, and four ORFs that code for the structural proteins spike, membrane, envelope and nucleocapsid (Marra et al., 2003; Rota et al., 2003) . The eight ORFs for subgroup-specific accessory proteins are thought to be dispensable for viral replication in cell culture (Yount et al., 2005) , but may be important for virus-host interactions, and thus contribute to the virus fitness and the viral pathogenesis in the natural host (de Haan et al., 2002; Ortego et al., 2003; Haijema et al., 2004) .
The accessory protein 7a (also known as X4 or U122) is a type I membrane protein of 122 amino acids. It contains an amino-terminal signal sequence, which is cleaved off between residues 15 and 16, an ectodomain (residues 16-98), a transmembrane helix comprising residues 99-117, and a short intracellular part of only five residues. This carboxy-terminus (KRKTE) represents a functional endoplasmic reticulum (ER) retrieval motif. The major part of the protein is a hydrophilic ectodomain that is oriented inside the lumen of the ER/Golgi or on the surface of either the cell membrane or the virus particle, depending on the localization of the protein. Experiments to investigate the subcellular localization in Vero E6 cells show that 7a is present in the ER compartment, probably in the ER/Golgi intermediate compartment (Fielding et al., 2004) , the trans-Golgi network and also on the cell surface of infected cells Nelson et al., 2005) . Recently, it was shown that 7a is contained in viral particles (Huang et al., 2006a) .
So far, only one host protein, the cellular small glutamine-rich tetratricopeptide repeat-containing protein SGT (Fielding et al., 2006) was shown to interact with protein 7a. SGT has been shown to be involved in many cellular processes including cell cycle control, transcription and splicing events, protein transport and protein folding (Blatch and Lassle, 1999) . Whether there is a biological significance of the interaction between 7a and SGT remains to be elucidated. In addition to SGT, two SARS-CoV proteins were shown to interact with 7a, namely the Spike protein (Huang et al., 2006a) and protein 3a (Tan et al., 2004b) .
It was reported that 7a is able to induce apoptosis via the caspase pathway in various cell types (Tan et al., 2004a; Kopecky-Bromberg et al., 2006) . Also, protein 7a is able to block cell cycle progression at the G0/G1 phase by reducing the expression levels of cyclin D3 and phosphorylation of retinoblastoma protein (Yuan et al., 2006) . Furthermore, overexpression of protein 7a inhibits cellular protein synthesis and induces the phosphorylation and activation of p38 mitogen-activated protein kinase (Kopecky-Bromberg et al., 2006) . Recently, it was shown that 7a is able to activate nuclear factor kB and c-Jun N-terminal kinase, and to enhance interleukin promoter activity (Kanzawa et al., 2006) .
The three-dimensional structure of the 7a ectodomain has been solved by X-ray crystallography (Nelson et al., 2005) and nuclear magnetic resonance (NMR) (Hanel et al., 2006) . It represents a novel variation of the immunoglobulin like b-sandwich fold. Because 7a does not reveal significant sequence homologies to proteins in the databases, a structure based similarity search for proteins with known function was carried out. We found a high structural similarity of the 7a ectodomain to the D1 domain of ICAM-1. In addition, we analyzed the 7a ectodomain structure in more detail and found additional elements of the interaction interface between ICAM-1 D1 domain and LFA-1 I domain to be present in 7a as well, e.g., the characteristic glutamic acid residue that is sur- ) were activated with 50 nM PDBu for the indicated time periods. After incubation with 3.2 mM (corresponds to 16 mg in 500 ml incubation volume) protein 7a for 1 h, the cells were washed and the amount of cell-bound protein 7a was analyzed by Western blotting of the total cell protein after electrophoretic separation. As a positive control, 20 ng 7a were applied to the rightmost lane.
rounded by a ring of hydrophobic residues. Based on these findings we predicted 7a to possess binding activity for the a L integrin I domain of LFA-1 (Hanel et al., 2006) .
ICAMs are cell adhesion molecules expressed on the surface of cells, especially on endothelial cells after cytokine-mediated stimulation at inflammatory sites. ICAMs belong to a subset of Ig-like superfamily proteins, which are specialized for binding to integrins. Integrins, in general, are non-covalently associated a/b heterodimeric transmembrane proteins, which are involved in adhesive cell-cell interactions. ICAM-1 and ICAM-2 are known to specifically interact with lymphocyte functionassociated antigen 1 (LFA-1, CD11a/CD18, a L b 2 integrin) that is expressed exclusively on leucocytes. Interactions between ICAMs and LFA-1 play a crucial role in lymphocyte homing to inflammation sites and in various intercellular cooperations during the specific immune response.
LFA-1 is reported to exist in three different conformations (Kinashi, 2006; Nishida et al., 2006) . A bent or switchblade-like conformation with the headpiece, which is responsible for ligand-binding, in close proximity to the membrane shows low-affinity to the ligand and is referred to as the 'bent' or 'low affinity' state. The other two forms of LFA-1 have an extended conformation, whereas the receptor including the headpiece is upright. In this upright orientation, the headpiece adopts either a 'closed' state with intermediate affinity or an 'open' state with high affinity to the ligand.
The ICAM binding site of LFA-1 is contained within the 180 residue I domain of the headpiece of LFA-1. A characteristic feature of the I domain is the metal ion-dependent adhesion site with a divalent metal ion coordinated by acidic residues of the I domain and the ligand (Hynes, 2002) . Recombinant I domain represents the closed form. To investigate the open form, a pair of cystein residues was introduced to form a disulfide bridge that locks the activated form (Shimaoka et al., 2001 ). This I domain mutant, which mimics the active conformation, shows 10 000-fold increased affinity for ICAM (Shimaoka et al., 2001 (Shimaoka et al., , 2003 .
To prove or disprove the structure based prediction that SARS-CoV protein 7a binds to the I domain of the a L subunit of LFA-1, we carried out a series of experiments using recombinant protein 7a and recombinant wild type and mutant LFA-1 I domain, as well as LFA-1 expressing Jurkat cells.
Results and discussion
Based on the three-dimensional structure, we predicted SARS-CoV protein 7a to have a LFA-1 I domain binding activity (Hanel et al., 2006) . To investigate this predicted function, we carried out various assays using LFA-1 expressing Jurkat cells, recombinant protein 7a ectodomain and LFA-1 I domain wild type and mutant.
Protein 7a binds preferably to activated Jurkat cells
A remarkable feature of T lymphocyte interactions with other cells is the rapid progression from strong adhesion to de-adhesion. LFA-1, which is constitutively expressed on Jurkat cells (van Kooyk et al., 1993; Weber et al., 1997; Crucian et al., 2006) , has been shown to exist in an active and inactive form. The active form can be induced artificially by stimuli, such as phorbolester (PMA, PDBu) and antibodies, e.g., against CD3. In this process, phorbolesters induce the protein kinase C to phosphorylate the b-subunit of LFA-1. This, in turn, induces conformational changes in LFA-1 with the consequence that LFA-1 favors binding with its ligand, e.g., ICAM-1 for cell adhesion. This increase in affinity to its ligand cannot be attributed to an increase of the LFA-1 expression level upon PDBu (phorbol-12,13-dibutyrate) activation. As was shown by numerous other studies, activation of T cells with phorbolester does not result in elevated expression levels of LFA-1 within a time period of even 2 h (Rothlein and Springer, 1986; Dustin and Springer, 1989; Lo et al., 1989; Kucik et al., 1996; Crucian et al., 2006) .
ICAM-1 binds almost exclusively to LFA-1 I domain in its activated form (Dustin and Springer, 1989) . To compare protein 7a binding to LFA-1 of activated and nonactivated Jurkat cells, the cells were activated nonspecifically by PDBu for 5 min, 20 min, 16 h or not at all, before 7a ectodomain was added to the cells. Non-activated Jurkat cells bound minor amounts of 7a ( Figure 1 ). After activation of the Jurkat cells, the amount of 7a bound to the cells was drastically increased. The level of 7a binding reached a maximum after 20 min and remained elevated for several hours. This experiment clearly shows that 7a preferably binds to activated Jurkat cells. However, in contrast to ICAM-1, 7a also binds to non-activated Jurkat cells to a significantly reduced extent. ICAM binding to LFA-1 was also reported to reach its maximum after 20 min of PDBu activation (Dustin and Springer, 1989) .
Protein 7a binds to LFA-1 on the surface of PDBuactivated Jurkat cells
To further investigate the potential LFA-1 binding activity of protein 7a, activated Jurkat cells were incubated with varying concentrations of recombinant protein 7a ectodomain for 1 h at 48C. After washing, cell bound 7a was immunoprecipitated, subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting ( Figure 2A ). Protein 7a is detectable in a concentration-dependent manner and reached satu- 6 PDBu-activated Jurkat cells were incubated with the indicated amounts (between 0 and 40 mg) of 7a protein in a total volume of 500 ml (corresponding to 7a concentrations between 0 and 8 mM). After washing, the cells were lysed and centrifuged.
Cell-bound protein 7a was immunoprecipitated with anti-7a antibody coupled to protein G Sepharose, washed, resuspended in 60 ml Laemmli buffer and 10 ml thereof were analyzed by Western blotting after electrophoretic separation. To verify that the binding capacity of anti-7a antibody loaded beads was not limiting in the experiment, 2 mg of 7a was added to cell extract and applied to the anti-7a antibody loaded protein G Sepharose beads before SDS-PAGE analysis and subsequent Western blotting ('C1'). To estimate the amount of total 7a protein on the Western blot, 10 ng of purified protein 7a was applied directly to the SDS-PAGE and subsequent Western blotting as well (right lane). (B) 4=10 5 PDBu-activated Jurkat cells in a total volume of 100 ml were incubated with 0.8 mg 7a (corresponds to a concentration of 0.8 mM) without any antibody ('no Ab') or with 0.8 or 4.0 mg (corresponds to concentrations of 0.06 or 0.3 mM, respectively) of various antibodies wanti-7a, anti-a L (clone 27), anti-a L (B43-25B), anti-b 2 x for 1 h. After washing, the cells were lysed and centrifuged. 7a protein in the supernatants was immunoprecipitated with anti-7a antibody coupled on protein G Sepharose, washed, resuspended in 50 ml Laemmli buffer, and 20 ml thereof analyzed with SDS-PAGE and subsequent Western blotting. To estimate the amount of total 7a protein on the Western blot, 2 ng and 20 ng of purified protein 7a were applied to the SDS-PAGE and subsequent Western blotting as well. It should be noted that the concentration of the anti-7a antibody in the experiment shown in lane 3 was 0.3 mM, which corresponds to 0.6 mM 7a binding sites. This is a little less than 0.8 mM 7a protein employed in the assay. However, from lane 2 in panel (A) it can be seen that the remaining 0.2 mM 7a leads to a very low binding ratio, which obviously could not be detected to any further extent in the anti-7a binding competition experiment shown in lane 3.
ration at 7a concentrations above 3 mM, corresponding to 15 mg in the assay. To verify that the observed saturation was not due to a limited binding capacity of the anti-7a antibody loaded beads used in the assay, 2 mg of 7a was directly applied to cell extract instead of living cells and subsequently immunoprecipitated with anti-7a antibody beads (control 'C1' in Figure 2A ). This clearly shows that the observed saturation is due to a limited number of receptors on the Jurkat cells. Although Western blotting is not the optimal method for the quantification of proteins, we intended to obtain an estimation of how many 7a molecules bound to one activated Jurkat cell. The right lane in the Western blot in Figure 2A represents 6 LFA-1 molecules per cell (Sung et al., 1992) . Thus, the number of binding sites for protein 7a per Jurkat cell is in the range of that reported for LFA-1 on T cell lines.
As a control, the presence of close to half-equimolar polyclonal anti-7a antibodies virtually abolished 7a binding of Jurkat cells ( Figure 2B ). Taken together, these data show that 7a is bound by activated Jurkat cells and the number of binding sites is limited, suggesting that Jurkat cells carry a specific receptor for 7a.
The 7a binding site on Jurkat cells is the a L subunit of LFA-1
Binding of 7a to Jurkat cells was inhibited in presence of a monoclonal anti-CD11a antibody 'clone 27' raised against residues 64-199 of the a L -subunit of LFA-1 (Figure 2B) . Therefore, although the exact epitope of antibody anti-CD11a (clone 27) is not known, it can be expected to be either within the I domain or close to the I domain. A monoclonal antibody increased against the b 2 -subunit did not interfere with 7a binding. Another antibody (clone G43-25B) directed against the a L -subunit of LFA-1 did not interfere with 7a binding either. The exact epitope of antibody G43-25B is not known. However, G43-25B is known not to block the ICAM-1/LFA-1 interaction (Mizuno et al., 1997) . This is in perfect agreement with the prediction that 7a binds to the same LFA-1 site as ICAM-1 does, which is the I domain of the a L subunit.
Direct in vitro binding of 7a to wild type and mutant I domain
Recombinant wild type I domain of LFA-1 is known to represent the non-activated conformation. This so-called 'closed' state of LFA-1 exerts low affinity to ICAM-1. A mutant I domain was described that mimics the active conformation having a 10 000-fold increased affinity for ICAM-1 (Shimaoka et al., 2003) .
To clearly identify the I domain of LFA-1 to be the 7a binding site, and to further investigate 7a binding to activated and non-activated I domain in a semi-quantitative way, wild type, as well as mutant I domain, were coated in wells of a microtiter plate and incubated with increasing concentrations of protein 7a. After thorough washing, the amount of 7a protein that was still bound to wild type or mutant I domain was determined by an ELISA employing anti-7a antibody and horseradish peroxidase (HRP) coupled anti-rabbit antibody as primary and secondary antibodies, respectively.
Wild type I domain bound 7a with a virtually linear concentration dependence. Up to 20 mM 7a, no saturation effect could be observed. Mutant I domain, as well, bound 7a in a strong concentration-dependent manner, LFA-1 expressing T cells (Lollo et al., 1993) . The same report assigns ICAM binding to non-activated T cells with a K d value of 100 mM.
Interestingly, the K287C/K294C mutant I domain was constructed to mimic the conformation with the highest affinity to ICAM-1. The prediction that 7a shows similar binding behavior as ICAM-1 implicates that 7a, too, binds more tightly to mutant I domain as compared to wild type I domain. This is exactly what was found in the ELISA (Figure 3 ). This underlines the similarities of the I domain binding surfaces of 7a and ICAM-1, exactly as predicted previously by us (Hanel et al., 2006 ).
An essential feature of the ICAM-1 LFA-1 interaction is its metal ion-dependency (Dustin and Springer, 1989; Shimaoka et al., 2001) . Neither the ELISA, nor the Jurkat cell binding assays were suitable to investigate the metal ion-dependence of 7a binding to wild type or mutant I domain (data not shown).
Potential biological implications of 7a interaction with LFA-1
The main target cells of SARS-CoV are bronchial epithelium cells, type I and II pneumocytes, T lymphocytes and macrophages/monocytes (Ye et al., 2007) . The clinical picture is characterized by a cascade of immunological events leading to pulmonary inflammation and respiratory failure (Hsiao et al., 2004; Openshaw, 2004) . High levels of cytokines and chemokines triggered by the host immune response to SARS-CoV are believed to contribute to the progressive pulmonary infiltration of macrophages (Nicholls et al., 2003) , neutrophiles and T cells (Jiang et al., 2005; Yen et al., 2006) . So far, the angiotensin-converting enzyme 2 (ACE2) (Li et al., 2003b) has been identified as the major receptor for SARS-CoV. ACE2 is expressed in various tissues, but mainly in endothelial cells including lung alveolar epithelial cells, enterocytes of the small intestine and arterial and venous endothelial cells (Harmer et al., 2002; Hamming et al., 2004) . Cathepsin L is discussed to play a role in the viral infection process (Chan et al., 2004; Huang et al., 2006b; Ye et al., 2007) . DC-SIGNR (L-SIGN, CD209L) and DC-SIGN (CD209) have been shown to enhance infection of ACE2-expressing cells (Jeffers et al., 2004; Marzi et al., 2004; Yang et al., 2005) , but are not able to mediate efficient infection in the absence of ACE2 (Jeffers et al., 2004; Marzi et al., 2004) . Expression of DC-SIGN is largely restricted to dendritic cells (Geijtenbeek et al., 2000) and alveolar macrophages (Soilleux et al., 2002) . DC-SIGNR is expressed in lymph node and liver sinusoidal endothelial cells (Pohlmann et al., 2001) .
In summary, all these findings suggest that receptors or cofactors not yet identified may be involved in the interaction between the virus and target cells. This is especially true for cell types that are reported to be infected by SARS-CoV, but do not express ACE2, e.g., T lymphocytes (Harmer et al., 2002; Hamming et al., 2004; Jiang et al., 2005) . LFA-1 is exclusively expressed on the surface of leukocytes. It mediates several adhesive interactions among cells of the immune system. Furthermore, LFA-1 mediates interactions of leukocytes with the endothelium and transendothelial migration of leukocytes (Bleijs et al., 2001; Ye et al., 2007) . The consequences of the hereby-characterized LFA-1 binding activity of 7a depend largely on the subcellular localization of 7a in infected cells or virus particles.
The presence of LFA-1 binding 7a molecules on the virus surface would allow the virus to use LFA-1 as an attachment factor or a receptor for cell entry. An interesting example is known from HIV-1, of which virus particles were found bearing incorporated host-encoded ICAM-1 on their surface. This led to a 5-to 10-fold increase in infectivity, caused by an interaction between virally incorporated ICAM-1 and cell surface LFA-1 (Fortin et al., 1997) . Indeed, 7a was recently reported to be localized on the virus surface (Huang et al., 2006a) , and although it was shown that SARS-CoV does not infect T cell lines in vitro (Hattermann et al., 2005) , SARS-CoV is reported to infect T cells and macrophages (Li et al., 2003a; Gu et al., 2005; Yen et al., 2006; Ye et al., 2007) . Thus, our observation that LFA-1 is a ligand of 7a could possibly suggest that LFA-1 is the SARS-CoV receptor in T cells. Alternatively, LFA-1 may act as an attachment factor for SARS-CoV that contributes to increased virus attachment to T cells. Protein 7a was already described to be primarily located in the ER of infected cells and to contain an ER retention signal (Fielding et al., 2004 ). An interaction of 7a with newly synthesized LFA-1 molecules in the ER could prevent LFA-1 delivery to the cell surface and consequently take influence on LFA-1 mediated functions. Prominent examples of viral accessory proteins with such functions are known from other viruses, e.g., HIV-1 Vpu binds to CD4 and prevents CD4 delivery to the cell surface and even induces its degradation (Schubert and Strebel, 1994; Schubert et al., 1998) .
The presence of 7a on the virus surface (Huang et al., 2006a) and all the data shown in the present study strongly suggest LFA-1 to be a viral attachment factor or even the SARS-CoV receptor of human leucocytes. Further, protein 7a should also be able to downregulate surface LFA-1 expression by inhibiting its delivery from the ER to the cell surface to decrease the risk of superinfection of already infected cells. Post-infective downregulation of viral receptors is a common feature of viral strategies. A prominent example is CD4 downregulation by HIV-1 proteins, Nef and Vpu.
Materials and methods

Cells and antibodies
Jurkat cells (DSMZ, ACC 282) were cultured in suspension in RPMI 1640 medium, 2 mM L-glutamine supplemented with 10% FCS (fetal calf serum; Biochrom AG, Berlin, Germany) and 50 mg/ml gentamycin under 5% CO 2 .
Anti-CD11a (clone 27), anti-CD11a (clone G43-25B, nonblocking for ICAM-1/LFA-1 interaction) and anti-CD18 (clone 6.7) mAbs were purchased from BD Pharmingen (San Diego, CA, USA). The secondary anti-rabbit mAb for Western blotting was purchased from Pierce (Rockford, IL, USA).
To obtain an antibody against SARS-CoV 7a protein, purified 7a ectodomain in native form was used for rabbit immunization (Eurogentec, Seraing, Belgium). The derived serum was used for immunoprecipitation experiments and Western blot analysis. For some experiments, anti-7a antibodies were purified using a 7a ectodomain to NHS-activated sepharose 4 fast flow (GE Healthcare, Munich, Germany). The specificity of protein 7a antibody was tested by ELISA. Pre-immune serum and serum of the final bleeding were tested in different dilutions (between 1:5000 and 1:40 000) against protein 7a or bovine serum albumin (BSA, as a control) coated on plastic. A positive signal was obtained only with serum from the final bleeding and protein 7a-coated wells.
Cloning and purification of recombinant protein 7a ectodomain and LFA-1 I domains SARS-CoV protein 7a ectodomain was expressed and purified as described earlier (Hanel et al., 2006) . To obtain wild type LFA-1 I domain, clone IRALp962H144Q (RZPD) was used as template for PCR. The cDNA of LFA-1 showed a deletion in the 59-region of the I domain. Synthetic primers (59-GGA AAA CTG AAC AGC AGC AAA CTG GTA CGA AGT GTT GCT GAG TTT CTT CAT CAC ATC CTT CAT GAA GTC CAG AAT TTT CTG AAA TTC ATC-39, and 59-GGA ATT CCA TAT GGT AGA CCT GGT ATT TCT GTT TGA TGG TTC GAT GAG CTT GCA GCC AGA TGA ATT TCA GAA AAT TCT GG-39) were used to generate a PCR amplificate coding for the amino-terminus of I domain.
The amplificate was used as forward primer to amplify the DNA that codes the I domain with the RZPD clone as template, and 59-CTG AGC TGC AGA AGA AGA TCT AAC GGG ATC CCG-39 as the reverse primer. Restriction sites, NdeI and BamHI, were used to insert the DNA into the multiple cloning site (MCS) of pET43b yielding the plasmid pID-wt DNA coding the a L highaffinity mutant K287C/K294C (Shimaoka et al., 2003) and was obtained by polymerase chain reaction (PCR) using the primers 59-GGA ATT CCA TAT GGT AGA CCT GGT ATT TC-39, and 59-CGG GAT CCC GTT AGA TCT TCT TCT GGA GCT CAG TGA ATA GAT CTT TCA GGC ACT CAA ATG TGT CCA GAA TGC ACA CAA ACT CGC TCG C-39. Again, restriction sites, NdeI and BamHI, were used to insert the DNA into the MCS of pET43b yielding the plasmid pID-mut. DNA sequences were confirmed by DNA sequencing. For expression of wild type and K287C/ K294C mutant I domain, plasmids pID-wt and pID-mut were transformed into BL21(DE3). Protein expression and purification was carried out as described previously (Legge et al., 2000) with minor modifications. Escherichia coli cells from 1 l expression culture were pelleted, resuspended in 30 ml buffer A w50 mM Tris-HCl, 2 mM dithiothreitol (DTT) and 2 mM EDTA pH 8x and lysed by sonification. After centrifugation at 15 000 g for 30 min, the supernatant was discarded and the pellet resuspended again in buffer A. This procedure was repeated 5-7 times to purify inclusion bodies. The inclusion bodies were solubilized in buffer B (6 M guanidinium hydrochloride, 50 mM Tris-HCl and 20 mM DTT pH 8) for 2 h and centrifuged at 15 000 g for 30 min. The protein concentration was adjusted to 1 mg/ml. For renaturation, the wild type I domain was rapidly diluted to 50 mg/ml in buffer C (50 mM Tris-HCl pH 8.5, 1 mM DTT, 1 mM MgSO 4 and 5% glycerol) and stirred overnight at 48C. Mutant I domain was refolded with buffer not containing DTT to allow formation of disulfide bridges. To remove denaturated protein the solution was filtrated, concentrated and loaded onto a Q-Sepharose column equilibrated in buffer C. Elution was performed with a 0-1-M NaCl gradient in buffer C. Wild type I domain eluted between 50 and 100 mM NaCl, the mutant I domain at 120 mM NaCl. (Legge et al., 2000) . In the case of the mutant I domain, the one-dimensional proton NMR spectrum was compared with the proton spectrum of wild type I domain. After reduction of the disulfide bridges in the presence of b-mercaptoethanol, both proton spectra were virtually identical (data not shown).
Jurkat cell surface binding of 7a
Jurkat cells were activated with 50 nM PDBu (phorbol-12, 13-dibutyrate; Sigma, Munich, Germany) at 378C for 20 min in RPMI 1640 medium supplemented with 5% FCS, 2 mM CaCl 2 and 2 mM MgCl 2 . Cells (500 ml; approximately 2=10 6 cells per tube) were immediately cooled on ice, incubated with varying (0.2-8 mM) concentrations of protein 7a for 1 h at 48C. To remove unbound protein, the cells were washed three times with icecold phosphate-buffered saline (PBS) and subsequently lysed in 500 ml lysis buffer wPBS with 1 mM MgCl 2, 5 mM octylthioglucosid (Sigma) and Complete Mini EDTA-free (Roche, Mannheim, Germany) Anti-Protease Mixturex for 30 min at 48C. After centrifugation with 20 000 g at 48C, the supernatant was incubated for 1 h at 48C with anti-7a antibody coated protein G sepharose beads (Amersham, Freiburg, Germany). The beads were washed three times with lysis buffer and then resuspended in Laemmli buffer and subjected to SDS-PAGE and Western blotting.
Western blotting
Sample aliquots were electrophoresed and transferred onto Immobilon-P QS membranes (Millipore, Schwalbach, Germany) using a semi-dry transfer unit (Hoefer, Munich, Germany) at room temperature for 15 min. The membrane was blocked with BSA containing TBST (Tris-buffered saline containing 0.1% Tween 20) for 1 h at room temperature and subsequently incubated with anti-protein 7a serum for 24 h at 48C. After washing the membrane three times with TBST buffer, the membrane was incubated with the HRP-coupled secondary anti-rabbit mAb for 24 h at 48C. After washing another three times with TBST, the membrane was incubated with SuperSignal west pico substrate (Pierce) according to manufacturer's recommendations for visualization of the bands with GelDoc 2000 System (Bio-Rad, Munich, Germany). For densitometric analysis, we used the program 'quantity one' version 4.4.0 (Bio-Rad).
ELISA
Solid-phase binding assays were carried out on 96 well plates coated with 100 ml of 0.5 mM wild type or mutant I domain in Tris-HCl-Mg-buffer (20 mM Tris-HCl, pH 7, 1 mM MgCl 2 ) overnight at 48C. Non-specific binding was blocked with 5 mg/ml BSA 1 h at room temperature. The plates were washed three times with 300 ml Tris-HCl-Mg-buffer containing 0.1% Tween 20.
Purified protein 7a was then added at concentrations from 0.125 mM to 20 mM in 100 ml Tris-HCl-Mg-buffer for 1 h at room temperature. After washing, the plates were incubated with anti-protein 7a serum diluted 1:15 000 in Tris-HCl-Mg-buffer containing 0.1% Tween 20. After 1 h at room temperature, the microtiter plates were washed, and HRP-conjugated anti-rabbit antibody (diluted 1:10 000) was added in Tris-HCl-Mg-buffer with 0.1% Tween 20 for 1 h at room temperature. After washing, 100 ml of a developing solution containing TMB (tetramethylbenzidine, Sigma) was added and incubated for 10 min at room temperature. The reaction was stopped with 100 ml of 2 M sulfuric acid and absorbance was measured at 450 nm. All values were obtained in triplicate and specific absorbance calculated by subtracting non-specific absorbance (in the absence of protein 7a) from total absorbance.
